🇺🇸 FDA
Pipeline program

AZD6738, Ceralasertib

D5339C00001

Phase 2 small_molecule active

Quick answer

AZD6738, Ceralasertib for Advanced Cancer Whose Tumours Contain Molecular Alterations is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Advanced Cancer Whose Tumours Contain Molecular Alterations
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials